Zentalis Pharmaceuticals, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Zentalis Pharmaceuticals, Inc. (ZNTL) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $143.65 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $143.65M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $182.68M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $216.20M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $252.87M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-06-30 | $143.65M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $182.68M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $216.20M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $252.87M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $274.50M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $295.38M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $337.19M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $354.33M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $382.58M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $458.77M 10-Q · filed 2025-08-06 | |
| 2023-12-31 | $437.39M 10-K · filed 2026-03-26 | |
| 2023-09-30 | $481.90M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $523.28M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $385.67M 10-Q · filed 2024-08-09 | |
| 2022-12-31 | $434.02M 10-K · filed 2026-03-26 | |
| 2022-09-30 | $428.74M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $472.82M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $315.67M 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $364.48M 10-K · filed 2025-03-26 | |
| 2021-09-30 | $394.00M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $247.61M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $292.64M 10-Q · filed 2022-08-09 | |
| 2020-12-31 | $333.38M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $365.83M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $237.93M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$89.19M 10-Q · filed 2021-08-12 | |
| 2019-12-31 | -$73.28M 10-K · filed 2023-03-01 | |
| 2019-09-30 | -$58.95M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $13.30M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $23.77M 10-Q · filed 2020-08-13 | -$23.59M 10-Q · filed 2020-05-15 |
| 2018-12-31 | $32.31M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |